Press Releases
Nov 20, 2024
PreciseDx Announces Formation of Scientific Advisory Board
See More
Nov 20, 2024
PreciseDx Announces Formation of Scientific Advisory Board
See More
Press Releases
Aug 21, 2024
PreciseDx Secures $20.7 Million Series B to Advance AI-Powered Cancer Risk Assessments
See More
Aug 21, 2024
PreciseDx Secures $20.7 Million Series B to Advance AI-Powered Cancer Risk Assessments
See More
Media Coverage
Aug 2, 2024
As AI-Based Diagnostics Proliferate, Stakeholders Strive for Regulation Without Stifling Innovation
See More
Aug 2, 2024
As AI-Based Diagnostics Proliferate, Stakeholders Strive for Regulation Without Stifling Innovation
See More
Press Releases
Jul 23, 2024
PreciseDx Announces Publication of Its Cost Impact Study, Payer Impact of PreciseBreast™ (PDxBr) to Identify Breast Cancer Recurrence, in the Journal Of Medical Economics
See More
Jul 23, 2024
PreciseDx Announces Publication of Its Cost Impact Study, Payer Impact of PreciseBreast™ (PDxBr) to Identify Breast Cancer Recurrence, in the Journal Of Medical Economics
See More
Publications
Jul 9, 2024
U.S. Payer Budget Impact of Using an AI-Augmented Cancer Risk Discrimination Digital Histopathology Platform to Identify High-Risk of Recurrence in Women with Early-Stage Invasive Breast Cancer
See More
Jul 9, 2024
U.S. Payer Budget Impact of Using an AI-Augmented Cancer Risk Discrimination Digital Histopathology Platform to Identify High-Risk of Recurrence in Women with Early-Stage Invasive Breast Cancer
See More
Publications
Jun 3, 2024
ASCO-24: AI-Enabled Digital Test to Predict Disease Recurrence for Patients with Early-Stage Invasive Breast Cancer Demonstrates Good Performance in a MammaPrint Low-risk Cohort from the Netherlands with a Median 6-year Follow-Up
See More
Jun 3, 2024
ASCO-24: AI-Enabled Digital Test to Predict Disease Recurrence for Patients with Early-Stage Invasive Breast Cancer Demonstrates Good Performance in a MammaPrint Low-risk Cohort from the Netherlands with a Median 6-year Follow-Up
See More
Press Releases
May 29, 2024
COTA, Baptist Health South Florida, and PreciseDx Announce Collaboration on the AI-Enabled Breast Cancer Recurrence Risk Assessment, PreciseBreast™
See More
May 29, 2024
COTA, Baptist Health South Florida, and PreciseDx Announce Collaboration on the AI-Enabled Breast Cancer Recurrence Risk Assessment, PreciseBreast™
See More
Press Releases
May 28, 2024
PreciseDx Announces Poster Presentation at The 2024 American Society of Clinical Oncology Annual Meeting
See More
May 28, 2024
PreciseDx Announces Poster Presentation at The 2024 American Society of Clinical Oncology Annual Meeting
See More
Press Releases
Apr 2, 2024
UCLA and PreciseDx Announce New Collaboration to Advance AI-Enabled Predictions and Risk Mitigation for Triple-Negative Breast Cancer Recurrence
See More
Apr 2, 2024
UCLA and PreciseDx Announce New Collaboration to Advance AI-Enabled Predictions and Risk Mitigation for Triple-Negative Breast Cancer Recurrence
See More
Publications
Mar 22, 2024
EBCC-14 Poster: Clinical validation of an artificial-intelligent (AI) enabled digital test using the patient's diagnostic breast biopsy to predict invasive breast cancer recurrence within 6-years.
See More
Mar 22, 2024
EBCC-14 Poster: Clinical validation of an artificial-intelligent (AI) enabled digital test using the patient's diagnostic breast biopsy to predict invasive breast cancer recurrence within 6-years.
See More
No results.
Contact us today to learn more about PreciseBreast.
